Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference


SAN DIEGO, March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of Viracta will present at the Oppenheimer 31st Annual Healthcare Conference taking place virtually from March 16-18, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

Presentation details can be found below.


Tuesday, March 16, 2021


2:30 p.m. ET

Webcast Link:

A replay of the presentation will be archived for 90 days on the "Events and Webcasts" section of the Viracta website at

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit

Investor Relations Contact:                                     

Company Contact:

Joyce Allaire                                                               

Dan Chevallard

LifeSci Advisors                                                          

Chief Operating Officer and Chief Financial Officer                             

(212) 915-2569                                                          

(858) 771-4193


Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)



Cision View original content to download multimedia:

SOURCE Viracta

Company Codes: NASDAQ-NMS:VIRX

Back to news